Table 3. Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in Switzerland and the US (Tables F-J in S1 File).
| Treatment regimens | Mean SVR, % (95% CI) | Mean costs, in Switzerland, USD (95% CI) | Mean costs per SVR in Switzerland, USD (95% CI) | Mean costs in US, USD (95% CI) | Mean costs per SVR in US USD (95% CI) |
|---|---|---|---|---|---|
| Step 1: IFN-α monotherapy | 11.89% (5.24%-18.53%) | 9,625 (7,736–11,514) | 81,026 (74,128–87,924) | 6,097 (-3,580–15,771) | 51,350 (41,406–61,295) |
| Step 2: IFN-α and RBV | 34.47% (27.82%-41.11%) | 22,375 (20,486–24,264) | 65,017 (58,119–71,915) | 25,064 (15,869–35,217) | 72,771 (64,826–82,715) |
| Step 3: pegIFN-α and RBV | 48.00% (44.16%-51.84%) | 34,419 (33,328–35,509) | 72,013 (68,030–75,996) | 36,515 (30,928–42,102) | 76,393 (70,651–82,134) |
| Step 4: First DAA protease inhibitors*, pegIFN-α and RBV | 74.96% (71.12%-78.79%) | 45,591 (44,500–46,682) | 61,151 (57169–65,134) | 76,082 (70-495-81,669) | 101,134 (95,393–106,876) |
| Step 5: New DAA† ± pegIFN-α and RBV | 96.30% (92.46%-1.00%) | 62,922 (61,831–64,012) | 65,422 (61,440–69,405) | 89,760 (84,172–95,347) | 93,393 (87,651–99,134) |
CI: Confidence Interval
* boceprevir; telaprevir; simeprevir
† sofosbuvir; ledipasvir; ritonavir-boosted paritaprevir, ombitasvir, and dasabuvir